Leavell Investment Management’s Altimmune ALT Stock Holding History

Leavell Investment Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,011	Closed	-$13K	–	371
2018 Q2	$13K	Hold	1,011	–	–	﹤0.01%	369
2018 Q1	$35K	Hold	1,011	–	–	﹤0.01%	370
2017 Q4	$60K	Buy	+1,011	New	+$64.6K	0.01%	372

Other funds holding ALT

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Leavell Investment Management's ALT Position: Q3 2018 in Review

Leavell Investment Management sold out of Altimmune (ALT) in Q3 2018, closing a stake of 1,011 shares — an estimated $13K sold.

Leavell Investment Management first reported a position in ALT in Q4 2017 and held it in 3 quarters. The position peaked at $60K in Q4 2017. 16 funds tracked by Wall St. Rank hold ALT as of Q3 2018.

Leavell Investment Management reported no remaining Altimmune position as of Q3 2018 after selling out during the quarter.
Leavell Investment Management sold 1,011 Altimmune shares in Q3 2018, an estimated $13K.
Leavell Investment Management first reported a position in Altimmune in Q4 2017 and held it in 3 quarters.
Leavell Investment Management's Altimmune position peaked at $60K in Q4 2017.
16 funds tracked by Wall St. Rank held Altimmune as of Q3 2018.

Based on Leavell Investment Management's 13F filing for Q3 2018, filed 22 Oct 2018.